TELA Bio Appoints Kurt Azarbarzin to Board of Directors
November 06, 2018 at 08:30 am EST
Share
TELA Bio, Inc. announced that the company has appointed Kurt Azarbarzin to its board of directors. Mr. Azarbarzin will replace vacating TELA Bio director Paul Touhey. Mr. Azarbarzin currently serves as chief technology officer of CONMED Corporation where he leads research and development across all subsidiaries and business units. He was previously founder and chief executive officer of SurgiQuest, Inc.
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
TELA BIO, INC. 
